BioSpace News Archive

Vizient, Inc. , the nation’s largest health care performance improvement company, today announced an opportunity for minority-, women- and veteran-owned businesses to enroll in its Community Contracting Program, a new initiative designed to connect Vizient member hospitals with local, diverse suppliers and service providers. When launched to its member hospitals, Community Contracting will streamline identification and co

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the Company’s culture and clinical and pre-clinical programs.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020.

The global human vaccines market is prophesied in a report by Transparency Market Research to stay consolidated until the end of the forecast period 2016-2024.

Rapidly changing technologies in the healthcare sector resulting in increased training needs of personnel is anticipated to account for marked growth of the healthcare education solutions market in the near future.

Chronic and viral diseases continue to cast their ugly shadow on the world with high transmission rates and increasing fatalities.

The outsourcing of biologics has seen a tremendous rise over the years prominently due to its benefits such as decreased investment in drug development and large-scale provision of manufacturing capabilities.

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company that the National Medical Products Administration of China has accepted the supplemental New Drug Application for TYVYT® in combination with Gemzar® and platinum as first-line therapy in squamous non-small cell lung cancer.

Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce that it has recorded its first sale of OxC-beta™ Livestock in Brazil.